About zai lab - ZLAB
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.
ZLAB At a Glance
Zai Lab Ltd.
899 Halei Road
Shanghai, Shanghai 201203
| Phone | 86-21-6163-2588 | Revenue | 399.19M | |
| Industry | Biotechnology | Net Income | -257,231,957.27 | |
| Sector | Health Technology | 2024 Sales Growth | 49.796% | |
| Fiscal Year-end | 12 / 2025 | Employees | 1,869 | |
| View SEC Filings |
ZLAB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 6.492 |
| Price to Book Ratio | 3.357 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -7.12 |
| Enterprise Value to Sales | 4.673 |
| Total Debt to Enterprise Value | 0.082 |
ZLAB Efficiency
| Revenue/Employee | 213,583.801 |
| Income Per Employee | -137,630.796 |
| Receivables Turnover | 4.465 |
| Total Asset Turnover | 0.359 |
ZLAB Liquidity
| Current Ratio | 3.509 |
| Quick Ratio | 3.376 |
| Cash Ratio | 2.938 |
ZLAB Profitability
| Gross Margin | 62.941 |
| Operating Margin | -70.708 |
| Pretax Margin | -64.439 |
| Net Margin | -64.439 |
| Return on Assets | -23.153 |
| Return on Equity | -31.427 |
| Return on Total Capital | -25.869 |
| Return on Invested Capital | -31.015 |
ZLAB Capital Structure
| Total Debt to Total Equity | 18.251 |
| Total Debt to Total Capital | 15.434 |
| Total Debt to Total Assets | 12.943 |
| Long-Term Debt to Equity | 1.631 |
| Long-Term Debt to Total Capital | 1.379 |